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PARP INHIBITION INCREASES SENSITIVITY OF 
NSCLC CELLS TO CISPLATIN 
Raya Rausch, Martin P. Barr, Juergen Thomale, Derek Richard, 
Kenneth O‘Byrne 
 
Background:  
Primary and acquired resistance to platinum agents 
is a serious clinical problem in lung cancer. Its mechanisms are probably 
multifactorial and remain poorly understood. Enhanced DNA 
repair can lead to increased cell viability in the face of DNA damage 
and has been proposed to be important in mediating platinum 
resistance. PARPs (poly(ADP-ribose) polymerases) are a family of 
nuclear enzymes that regulate the repair of DNA single-strand 
breaks (SSBs). Cisplatin sensitivity and DNA repair mechanisms 
following treatment with the PARP inhibitor, PJ34, was investigated 
in this study. 
 
Methods:  
A panel of isogenic cisplatin resistant (CisR) NSCLC cells 
lines (MOR, SKMES-1, H1299) previously generated in our laboratory 
were used. The cisplatin resistant phenotype was initially 
assessed by treating CisR and parental (PT) cells with increasing 
doses of cisplatin (0-80uM) for 72h, after which time, cell proliferation 
was measured (BrdU). The effects of PJ34 on cell survival were 
also examined in a similar dose-response study. IC25 concentrations 
were calculated for each cell line using GraphPad statistical 
software. Cells were treated with PJ34 (IC25) alone, or in combination 
with cisplatin and cell survival/proliferation measured after 
72h. Under similar experimental conditions, RNA was isolated from 
cells from which cDNA was reverse transcribed. All cell lines were 
screened for PARP1, PARP2, BRCA1, BRCA2 and ERCC1 mRNA at 
basal levels, and in response to treatment (RT-PCR). To investigate 
DNA double strand break (DSB) repair capacity in our panel of cell 
lines in response to PARP inhibition and cisplatin, phosphorylated 
γH2AX foci was examined by High Content Analysis (HCA) following 
treatment of cell lines for 24h. Cisplatin-DNA adduct formation 
(Pt-GpG) was studied following treatment of cells for 24h. 
Cells (1x106/ml) were spotted on Superfrost® Gold glass slides. 
Immunofluorescence staining of specific DNA platination products, 
and quantification of adducts, was performed using an antibody 
that specifically recognises cisplatin-GpG DNA adducts. 
 
Results:  
MOR and H1299 CisR cells were significantly more resistant 
to cisplatin (10μM and 20μM) compared to PT cells. SKMES-1 
CisR cells were also significantly more resistant at 10μM, 20μM and 
40μM cisplatin. While PJ34 had no effect on NSCLC cells when treated 
as a single agent, cell proliferation was significantly inhibited 
in MOR and H1299 cells when used in combination with cisplatin. 
No effect however was observed in our panel of CisR cell lines. 
While baseline expression levels of PARP1/2, BRCA1/2 and ERCC1 
mRNA levels were similar in PT and CisR cell lines, BRAC1/2 mRNA 
expression was increased in cells treated with cisplatin alone, 
and in combination with PJ34 in PT cells but not in CisR cells. The 
formation of γH2AX foci and measurement of cisplatin-GpG DNA 
adducts in response to PARP inhibition and cisplatin are currently 
being investigated. 
 
Conclusion:  
Data from this study show that inhibition of NSCLC 
cells with the PARP inhibitor, PJ34, sensitises lung cancer cells 
to the cytotoxic effects of the platinum drug, cisplatin. Further 
studies are warranted to investigate the role of PARP inhibitors in 
cisplatin resistant NSCLC cells. 
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